Bevacizumab biosimilar (Pfizer)

贝伐珠单抗生物类似药（辉瑞）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBevacizumab biosimilar (Pfizer)
Drug Alias Name贝伐珠单抗生物仿制药（辉瑞）bevacizumab-bvzr贝伐人源化单抗生物仿制药（辉瑞）贝伐赛珠单抗生物仿制药（辉瑞）贝伐单抗生物仿制药（辉瑞） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/02/14
Country/TerritoryCzechiaBulgariaUnited States +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Europe Ma Eeig
Inactive CompaniesHospiraGe Medical Systems Trade & Development (Shanghai) Co LtdPfizer Biologics(Hangzhou)Company Ltd
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A